Wechat scan consulting
Wechat scan consulting
23
November 3, 2026 | Beijing, China
Daxiang Biotech and Molecular Devices, a Danaher company, have taken an important step in strengthening their collaboration with the signing of an agreement to jointly establish an Organoid and Organoid-on-a-Chip Innovation R&D Center, alongside the inauguration of a translational platform in Beijing, China.
The signing ceremony was held during the 5th Symposium on 3D Cell Organoids and High-Content Imaging Technologies, bringing together scientific experts, researchers, and industry representatives to explore advances in organoid research and related technologies.
The event was attended by senior representatives from both organizations, including Mary Duseau, Global President of Molecular Devices, and Yu Zhou, Founder and CEO of Daxiang Biotech, together with Daxiang Biotech's CTO and other members of both teams.
During the opening ceremony, Yu Zhou shared Daxiang Biotech's vision for advancing organoid and organoid-on-a-chip technologies and their applications in biomedical research and drug discovery. Dr. Duanchen Ding, R&D Director of Daxiang Biotech, delivered a technical presentation highlighting the company's technological capabilities and progress in organoid-based research applications.
The collaboration builds on a relationship established in 2023 and reflects a shared interest in advancing organoid research through complementary technological capabilities.
Daxiang Biotech brings expertise in organoid and organoid-on-a-chip technologies, supported by its proprietary IBAC® chip platforms and Oakuloid™ AI-powered drug modeling platform.
Molecular Devices contributes capabilities in automated cell culture, high-content imaging, and intelligent analytical technologies. Its CellXpress.ai® Automated Cell Culture System integrates automated cell handling, culture monitoring, imaging, and machine learning-assisted decision-making to support standardized and scalable 2D and 3D cell culture workflows, including organoid applications.
By connecting these capabilities, the two companies aim to explore integrated workflows spanning organoid model construction, automated culture and imaging, and AI-powered data analysis.
Through the joint innovation R&D center and translational platform, the two organizations plan to explore collaboration in several areas:
Application Method Development: Developing and optimizing experimental methods and standardized protocols for organoid and organoid-on-a-chip applications.
Technology Demonstration and Training: Supporting demonstration testing, technical exchanges, and training for pharmaceutical companies and research institutions.
Joint Application Validation: Exploring applications in drug discovery, disease modeling, regenerative medicine, and other areas of biomedical research.
Scientific and Industry Engagement: Promoting knowledge exchange through technical presentations, academic collaboration, and industry education.
The collaboration aims to connect advanced biological models with automated experimentation and intelligent analytical technologies, supporting the development of more standardized, efficient, and application-oriented research workflows.
As organoid technologies continue to evolve, collaboration across biological modeling, automation, imaging, and AI-driven analysis will be increasingly important in advancing human-relevant research.
Building on their established relationship, Daxiang Biotech and Molecular Devices look forward to exploring further opportunities for scientific and technological collaboration and supporting the broader application of organoid-based models in biomedical research and drug development.
Together, advancing the next generation of human-relevant research.
